Clinical Trial Update: A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on F182112 for relapsed or refractory multiple myeloma; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Multiple Myeloma

Drugs mentioned

• F182112 (F182112)

Snippet

Sponsor: Shandong New Time Pharmaceutical Co., LTD | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 2 | Status: RECRUITING